Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, announced the close of its seed financing. The close brings total capital raised to $6 million since the company's founding in 2025. Investors include Unshackled Ventures, 1517 Fund, and Narya.